Henceforth, the XBP-1s/PDI/MTP axis has emerged as a potential therapeutic target for the treatment of lipid metabolism disorders, especially hypertriglyceridemia [12], despite the plethora of other regulatory targets. This evidence concerns the gene MTTP and hypertriglyceridemia.